Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study

<div>Survival analysis of the HH group (ER &gt; 10%/PR &gt; 20%), HL group (ER &gt; 10%/1% ≤ PR ≤ 20%), and LL group (1% ≤ ER ≤ 10%/1% ≤ PR ≤ 20%). Kaplan–Meier survival curves were plotted, and the log rank test was performed to compare the overall survival and disease free survival among the three groups.</div>

The Breast Journal

fig3

Figure 3

Figure 3: Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study 

Figure 3 | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study 